HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Shizuya Yamashita Selected Research

evolocumab

11/2020Evolocumab Effects on Lipoproteins, Measured by High-Performance Liquid Chromatography.
1/2014Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk--primary results from the phase 2 YUKAWA study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Shizuya Yamashita Research Topics

Disease

45Atherosclerosis
01/2024 - 01/2002
29Cardiovascular Diseases (Cardiovascular Disease)
12/2023 - 05/2002
27Hypertriglyceridemia
04/2024 - 01/2004
26Dyslipidemias (Dyslipidemia)
04/2024 - 03/2005
25Coronary Artery Disease (Coronary Atherosclerosis)
04/2024 - 01/2004
23Hyperlipoproteinemia Type II (Familial Hypercholesterolemia)
01/2024 - 01/2004
18Hyperlipidemias (Hyperlipidemia)
11/2020 - 05/2002
15Coronary Disease (Coronary Heart Disease)
09/2023 - 04/2003
15Xanthomatosis (Xanthoma)
06/2022 - 08/2005
11Type 2 Diabetes Mellitus (MODY)
05/2023 - 09/2008
10Inborn Genetic Diseases (Disease, Hereditary)
05/2024 - 09/2002
9Insulin Resistance
12/2023 - 05/2003
8Cholesteryl Ester Transfer Protein Deficiency
03/2019 - 07/2002
8Metabolic Syndrome (Dysmetabolic Syndrome X)
02/2017 - 12/2006
6Inflammation (Inflammations)
01/2023 - 01/2012
6Hypertension (High Blood Pressure)
05/2022 - 01/2004
6Tangier Disease
08/2021 - 08/2002
6Obesity
02/2017 - 01/2005
5Fibrosis (Cirrhosis)
04/2024 - 01/2013
5Hypercholesterolemia
01/2024 - 09/2010
5Cardiomyopathies (Cardiomyopathy)
01/2022 - 01/2013
5Hyperlipoproteinemia Type III (Broad Beta Disease)
02/2017 - 06/2003
5Platelet Glycoprotein IV Deficiency
01/2012 - 05/2003
4Non-alcoholic Fatty Liver Disease
04/2024 - 11/2016
4Myocardial Infarction
01/2023 - 01/2012
4Fatty Liver
12/2022 - 02/2002
4Drug-Related Side Effects and Adverse Reactions
06/2018 - 01/2016
3Heart Failure
04/2024 - 01/2013
3Cardiomegaly (Heart Hypertrophy)
04/2024 - 01/2019
3Diabetes Mellitus
07/2023 - 01/2004
3Hyperglycemia
07/2023 - 05/2009
3Sitosterolemia
08/2021 - 09/2010
3Stroke (Strokes)
06/2020 - 01/2019
3Chronic Renal Insufficiency
06/2020 - 09/2010
3Body Weight (Weight, Body)
02/2018 - 01/2015
3Hypothyroidism
02/2017 - 11/2009
3Hyperlipoproteinemia Type I (Lipoprotein Lipase Deficiency, Familial)
09/2013 - 09/2008
3ST Elevation Myocardial Infarction
01/2012 - 05/2010
2Peripheral Arterial Disease
04/2024 - 01/2016
2Carotid Artery Diseases
06/2022 - 11/2005
2Pancreatitis
11/2020 - 09/2013
2Metabolic Diseases (Metabolic Disease)
01/2020 - 05/2019
2Liver Diseases (Liver Disease)
01/2020 - 02/2011
2Hypoxia (Hypoxemia)
10/2019 - 10/2002

Drug/Important Bio-Agent (IBA)

42oxidized low density lipoproteinIBA
01/2024 - 10/2002
30Lipoproteins (Lipoprotein)IBA
05/2024 - 05/2003
30LipidsIBA
01/2024 - 01/2002
30LDL CholesterolIBA
12/2023 - 01/2002
28CholesterolIBA
12/2023 - 01/2002
21HDL CholesterolIBA
04/2024 - 07/2002
21Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
11/2023 - 05/2002
20(R)-2-(3-((benzoxazol-2-yl-d4 (3- (4- methoxyphenoxy- d7)propyl)amino)methyl)phenoxy) butanoic acidIBA
04/2024 - 01/2018
19Triglycerides (Triacylglycerol)IBA
04/2024 - 09/2005
16LDL Lipoproteins (beta Lipoproteins)IBA
06/2022 - 01/2004
16HDL LipoproteinsIBA
08/2021 - 08/2002
16Apolipoprotein B-48IBA
02/2017 - 06/2003
10ChylomicronsIBA
05/2024 - 06/2007
10Probucol (Lorelco)FDA Link
06/2022 - 11/2005
9ApolipoproteinsIBA
05/2024 - 02/2002
8Ezetimibe (Zetia)FDA Link
11/2023 - 09/2010
7Glucose (Dextrose)FDA LinkGeneric
01/2021 - 05/2007
7Cholesterol Ester Transfer ProteinsIBA
03/2019 - 07/2002
7Proteins (Proteins, Gene)FDA Link
03/2019 - 01/2004
7AdiponectinIBA
01/2015 - 03/2005
6Fenofibrate (CiL)FDA LinkGeneric
06/2018 - 06/2010
6LDL Receptors (LDL Receptor)IBA
06/2018 - 10/2002
6Chylomicron RemnantsIBA
02/2017 - 06/2007
5Peroxisome Proliferator-Activated Receptors (PPAR)IBA
04/2024 - 01/2018
5Fibric Acids (Fibrates)IBA
05/2023 - 08/2003
5Apolipoproteins E (ApoE)IBA
01/2018 - 08/2003
4Biomarkers (Surrogate Marker)IBA
12/2023 - 07/2011
4Lipoprotein(a)IBA
11/2022 - 09/2008
4AntioxidantsIBA
02/2021 - 12/2008
4Apolipoprotein A-I (Apolipoprotein A1)IBA
10/2008 - 08/2005
3Apolipoproteins B (ApoB)IBA
05/2024 - 09/2005
3hydroxide ionIBA
12/2023 - 11/2009
3campesterolIBA
07/2023 - 09/2010
3Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA
05/2023 - 02/2017
3Bile Acids and Salts (Bile Acids)IBA
12/2022 - 09/2010
3gamma-sitosterol (beta-sitosterol)IBA
08/2021 - 09/2010
3ProgranulinsIBA
01/2020 - 10/2013
3Adenosine Triphosphate (ATP)IBA
01/2019 - 08/2002
3Insulin (Novolin)FDA Link
01/2019 - 01/2015
3Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
09/2015 - 03/2005
3Niacin (Nicotinic Acid)FDA LinkGeneric
05/2015 - 04/2012
3Hypolipidemic Agents (Antihyperlipidemics)IBA
01/2012 - 05/2002
2microsomal triglyceride transfer proteinIBA
05/2024 - 02/2002
2TabletsIBA
04/2024 - 11/2020
2C-Reactive ProteinIBA
12/2023 - 01/2012
2Nicotinic AcidsIBA
05/2023 - 01/2020
27-ketocholesterolIBA
12/2022 - 01/2020
2Phytosterols (Plant Sterols)IBA
08/2021 - 09/2010
2evolocumabIBA
11/2020 - 01/2014
2Omega-3 Fatty Acids (Omega 3 Fatty Acids)IBA
01/2020 - 02/2017
2Complement System Proteins (Complement)IBA
01/2020 - 03/2019
2Apolipoprotein C-IIIIBA
03/2019 - 03/2005

Therapy/Procedure

20Therapeutics
04/2024 - 08/2010
5Secondary Prevention
02/2021 - 05/2002
4Drug Therapy (Chemotherapy)
05/2023 - 09/2010
2Ligation
10/2019 - 01/2013